Alzheimer's disease is a very complex disease in which neuroinflammation and synaptic dysfunctions play a critical role in association with the two wellknown molecular agents of the disease, the Aβ 1-42 peptide oligomers and the hyperphosphorylated tau protein. Arachidonic acid, the main member of the ω-6 series, is quantitatively the second polyunsaturated fatty acid in brain and is mainly esterified in membrane phospholipids. It is specifically released by the cytosolic phospholipase A 2 whose inhibition or gene suppression counteract the deleterious effects of Aβ 1-42 peptide oligomers on cognitive abilities. Arachidonic acid can be reincorporated under the action of the acylCoA synthetase 4 and lysophospholipid acyltransferases which remain to be characterized. Free arachidonic acid can be involved in Alzheimer's disease through several mechanisms. First it is converted by cyclooxygenases-1/2 and the specific prostaglandin synthases into PGE2 and PGD2 which contributes to the occurrence and progression of neuroinflammation. Neuroinflammation has positive as well as negative effects, by favoring Aβ 1-42 peptide clearance on one hand and by increasing the production of neurotoxic compounds on the other hand. Second, free arachidonic acid is also involved in synaptic functions as a retrograde messenger and as a regulator of neuromediator exocytosis. Third, some studies indicated that free arachidonic acid and its derivatives activate kinases involved in tau hyperphosphorylation. In addition, the dietary intakes of arachidonic acid in western food increased in the last period. Taken together, these various reports support the hypothesis that arachidonic acid is interesting target in nutrition-based preventive strategies against this disease.
Introduction
All the recent clinical trials against Alzheimer's disease (AD) failed to evidence any efficiency against the sporadic or late onset cases. A better understanding of AD mechanisms is required to open new therapeutic or preventive strategies. Lipids are important actors in AD as shown by the numerous works devoted to the putative neuroprotective role of docosahexaenoic acid (DHA, C22:6 ω-3), the main polyunsaturated fatty acid (PUFA) in brain 1 . By contrast, the role of arachidonic acid (ARA, C20:4 ω-6) was less extensively studied, despite the fact that it is the second PUFA in the brain. ARA corresponds to around 20% of the total amount of the neuronal fatty acids and is mainly esterified in membrane phospholipids. After its release by phospholipases A 2 , ARA is converted by several enzymes into numerous eicosanoids which are actors of neuroinflammation 2 . But ARA can also be directly involved in synaptic functions as a free fatty acid 3 . Therefore, the level of intracellular free ARA and the balance between the releasing enzymes and those which allows its incorporation in membrane phospholipids can be critical for AD-associated phenomena such as neuroinflammation and synaptic dysfunctions. Both these events can be observed in AD murine models before the two historical pathognomonic AD signs, the amyloid plaques and the neurofibrillary tangles which are respectively formed by the two known AD agents, Aβ peptide and hyperphosphorylated tau. Finally, western food which contains excessive ω-6 / ω-3 ratios 4 (above the recommended value of 5) might favor its incorporation in brain lipids and its influence on AD mechanisms. As a consequence, a better knowledge of the relationship between ARA and these mechanisms is useful for the therapy or prevention of AD. These different points will be discussed in this mini-review.
Mobilization of arachidonic acid in neuronal and glial cells
Free ARA is released from membrane phospholipids by several phospholipases A 2 which constitute a superfamily including intracellular as well as secretory and Ca 2+ -dependent or -independent enzymes 5 . Group IVA PLA 2 (or cPLA 2 -α) is the only PLA 2 which specifically release ARA 6, 7 . This cytosolic enzyme is activated and translocated to membranes after a rise of cytosolic calcium concentration and the phosphorylation of its Ser 505 by the MAP-kinase cascade 7 (Figure 1, left) . The involvement of cPLA 2 -α in AD was first evidenced by its higher expression in AD patient brain 8 . Several works also showed that cPLA-α mediates the effects of Aβ 1-42 peptide in astrocytes and microglial cells 9, 10 . cPLA 2 -α is also expressed in neuronal cells 11, 12 which are protected from the pro-apoptotic effects of Aβ peptide oligomers by the reduction of its activity or expression It is re-incorporated in phospholipids after its conversion into arachidonyl-CoA by acyl-CoA synthetase 4 (ACSL4). Free ARA influences synaptic function by acting as retrograde messenger and by opening Kv channels which lead to exocytosis of neuromediator and induction of LTP. Top: arachidonic acid activates several kinases which directly or indirectly contribute to increase tau phosphorylation levels. Right: free Arachidonic acid is converted into PGG2 by cyclooxygenase-2 (COX-2) which is overexpressed in neuronal cells in Alzheimer's disease. PGG2 is converted in PGD2 and PGE2 by corresponding prostaglandin synthases in astrocytes and microglial cells. PGE2 bind to EP2 and EP4 receptors on microglial cell membranes. These receptors have different effects in neuroinfllammation, stimulation of Aβ clearance or production of neurotoxic molecules. These positive or negative effects illustrate the dual role of neuroinflammation. cPLA 2 -α phosphorylation. Several signaling pathways downstream of cPLA 2 -α activation have been characterized in neuronal cells such as stimulation of sphingomyelinase 13 or PLD2 14 activities. Finally, the critical role of cPLA 2 -α was definitively established by in vivo experiments showing that its gene suppression leads to resistance to Aβ peptide in a transgenic murine line bearing a double mutation of human APP 12 or in wild-type mice submitted to intracerebroventricular injections of Aβ peptide 15 . But the way by which cPLA 2 -α-released ARA mediates Aβ oligomer neurotoxicity remains to be identified.
Free ARA is incorporated into membrane phospholipids through two steps, 1) its esterification with Coenzyme A into arachidonyl-CoA by acyl-CoA synthetases (ACSLs), 2) its transfer from arachidonyl-CoA to lysophospholipids by various acyl-CoA lysophospholipids acyltransferases (LPATs). Among the various ACSLs, ACSL4 specifically esterifies ARA (Figure 1 , left) and was first described in steroidogenic tissues 16 . In addition to the ubiquitous isoform, a neuronal specific isoform was identified and differs from the first one by an additional 41 amino-acid N-terminal domain 17 . Mutant ACLS4 gene was associated to X-linked mental retardation 18 and has been involved in neuronal differentiation, axonal transportations and synapse formation 17, 18, 19 . Channeling of ARA by ACSL4 and Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) to phosphatitylinositol (PI) has been described in CHO cells 20 . But the role of the various LPATs in the ARA incorporation in brain phospholipids remains to be characterized in more details. ACLS4 and LPATs could reduce the free ARA level in neuronal and glial cells, thus limiting the impact of enhanced cPLA 2 -α activity on this level and the consequences on neuroinflammation and synapse dysfunctions.
Neuroinflammation and AD: role of arachidonic acid and its derivatives
Neuroinflammation plays a positive role in the early AD steps by contributing to Aβ peptide clearance but can contribute to synapse alterations in the advanced stage of the disease when Aβ peptide accumulates and aggregates in amyloid plaques 21 . Eicosanoids formed from free ARA are key mediators in neuroinflammation. Among the various enzymes which produced these eicosanoids, cyclooxygenases-1 and -2 (COX-1/COX-2) convert ARA into PGH2 22 . Then, PGH2 is used by various prostaglandin synthases to produce the various prostaglandins in the different tissues 23 . Nonsteroidal anti-inflammatory drugs (NSAIDs ) are well known inhibitors of COX-1 and COX-2. Their involvement in AD has first been suggested by studies which evidenced a reduction of AD risk in patients treated by NSAIDS [24] [25] [26] . In the majority of organs and tissues, COX-1 is constitutively expressed and COX-2 gene expression is induced especially in case of inflammation. On the contrary, brain tissues and especially neuronal cells constitutively express COX-2 in basic condition 27 ( Figure 1, left) . But COX-2 overexpression in brain of AD patients has been reported and correlated to the progression of the disease in several studies 28, 29 . Since Aβ 1-42 oligomers do not induce the COX-2 expression in human microglial cell primary cultures 30 , the COX-2 overexpression observed in AD patient brains is likely to be generated in neuronal cells. On the contrary to COX-2, COX-1 is overexpressed by microglial cells around amyloid plaques 31 . In addition, the expression of COX-3, a splice variant of COX-1, has also been reported in AD hippocampus and Aβ 1-42 treated neuronal primary culture neuronal cells 32 . PGH2 can be secreted by neuronal cells and converted into other prostaglandins by glial cells. In the brain, the most abundant prostaglandins are PGD2 and PGE2 (Figure 1, left) , which are synthetized by several PGD2 and PGE2 synthases. Expression levels of hematopoietic PGD2 synthase (one of the two PGD2 synthases expressed in the brain) are enhanced in microglial cells and astrocytes of AD transgenic mice and patients 33 . As a result PGD2 is overproduced in these glial cells surrounding the amyloid plaques 33 . PGE2 binds to several receptors and have opposite effects on inflammation depending on the receptor type. EP2 receptor mediates negative inflammatory effects (Figure 1 , right) since its gene suppression reduces the microglial toxic inflammatory response and restored Aβ clearance 34 . By contrast, suppression of the EP4 receptor increases the inflammatory response in the brain of the APPSwe-PS1ΔE9 mouse 35 .
Five-lipoxygenase (5-LOX) converts free ARA into 5-hydroxyperoxyeicosatetraenoic acid , which is then stabilized into 5-hydroxyeicosatetraenoic acid (5-HETE) or converted by 5-LOX into leukotriene A4 (LTA4).
5-LOX gene deletion attenuates the worsening effect of LPS-induced neuroinflammation in transgenic AD-model mice
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. But the use of 5-LOX inhibitors demonstrated that 5-LOX and its products have a stronger impact on Aβ peptide production and tau phosphorylation in neuronal cells 37 than in the proliferation of glial cells and neuroinflammation.
Despite the data of retrospective epidemiologic studies which reported a lower AD risk in NSAIDStreated populations, randomized controlled trial failed to support the efficiency of these drugs in the AD therapy 26, 38 . Therefore, other approaches are needed to explain the discrepancy between the data of the observational studies or the works on AD animal models on one hand and those of the clinical trials on the other hand. Parallel mechanisms could explain the role of COX inhibitors in AD. For example, higher plasma concentrations of tryptophan metabolites were found in AD patients suggesting the involvement of the kynurenine pathway which influences the serotoninergic and glutamatergic neurotransmission 39 . Ibuprofen drastically reduced the expression of the neuronal tryptophan 2,3-dioxygenase (Tdo2), which encodes an enzyme that metabolizes tryptophan to kynurenine while Tdo2 inhibition prevented behavioural deficits in the AD model APPSwe-PS1ΔE9 mice 40 . However, the influence of ARA and its metabolites on Tdo2 expression remains to be established.
Arachidonic acid and synaptic functions
Before its deposit in amyloid plaques, Aβ 1-42 peptide forms oligomers which are now recognized as the main pathological actor in the early steps of AD. These oligomers initially alter the remodeling of the synaptic network and memory abilities by inhibiting long-term potentiation (LTP) 41 . Free ARA produced by the postsynaptic neuron acts as a retrograde messenger which increases the neurotransmitter release by the presynaptic neuron and results in the induction of LTP 42 ( Figure 1, left) . Regulation of the pre and post-synaptic Kv channels by ARA is also involved in its effect on LTP 43 . Moreover the LTP was reduced by cPLA 2 -α gene suppression or its inhibition by arachydonyl trifluoromethyl ketone (AACOCF3) 44 . Thus ARA seems to be necessary for the LTP induction.
Free ARA activates the soluble N ethylmaleimideattachment receptors (SNARE), which are required for the fusion of synaptic vesicles with the plasma membrane 45 ( Figure 1, left) . Vesicle SNARE protein VAMP-2 interacts with the plasma membrane SNARE proteins SNAP25 and syntaxin-1 to form a complex which promotes membrane fusion. ARA induces the binding of syntaxin-1 to the SNARE complex in presence of Munc18-1, which is a critical regulator of this process 46 . The involvement of ARA in the vesicle membrane fusion was also demonstrated by the formation of TIP30 complex which associates Tip30 endophilin B and ACSL4 47 . In this complex, TIP30 transfers ACSL4-produced arachidonyl-CoA onto phosphatidic acid and thus forms new species which induce close contact between membranes. Initial work on neuroendocrine cells revealed increased ARA production during exocytosis and clearly showed that ARA provision facilitated vesicular release 48 . Taken together, these studies support the hypothesis that modulation of free ARA levels can impact synaptic functions. Excessive maintenance of LTP or release of neurotransmitter could result from excessive levels of free ARA levels and have detrimental effects on memory storage.
Arachidonic acid and tau
Tau is a microtubule associated protein which is physiologically weakly phosphorylated and concentrated in the neuronal axons 49 ( Figure, top) . The C-terminal domain of Tau binds to α and β-tubulin to assemble microtubules and regulates the axonal transport of neurotransmitters. In AD, an excessive kinase activity and/or a shortfall of phosphatase activity lead to Tau hyperphosphorylation 49 . Hyperphosphorylated Tau accumulates in the dendrites and cell body of the neuron, forms helical filaments and subsequently neurofibrillary tangles 50 .
Several studies reported that free ARA in vitro induced tau polymerization. The ARA concentration required for the polymerization differs according to the various tau isoforms which are generated by alternative splicing 51 . These polymers activate microglial cells 52 
.
Among the various kinases which phosphorylate tau, two enzymes, PKNα and PKCξ bind and are activated by ARA 53, 54 . PKNα is one of the 3 PKC-homologous serine/ protein kinases (PKN), is highly expressed in brain 54 and accumulates in neurofibrillary tangles 55, 56 . Increased expression levels of PKCξ, an atypical Protein Kinase C family member, have been measured in neuronal membrane fraction of AD TG2576 mice 57 and in T-lymphocytes of patients affected by severe forms of AD Lipoxygenase-generated derivatives of ARA are also involved in tau phosphorylation. Suppression of 5-LOX gene expression improves Tau and Aβ-related mechanisms in AD mouse models 60 . In addition, the dual enzyme 12/15-lipoxygenase and its products, 12(S)-HETE and 15(S)-HETE modulates Tau metabolism specifically via the cdk5 kinase pathway 61 .
Conclusion
Free ARA contributes to AD progression through various mechanisms. Through its conversion into pro-inflammatory eicosanoids, it participates to neuroinflammation. ARA is directly involved in synaptic functions as a retrograde messenger and a regulator of neuromediator exocytosis. Finally, some works also indicate that ARA might have some influence on tau phosphorylation and polymerization. All these data shows that ARA has pleiotropic effects in AD and might be an interesting target in the fight against this complex disease.
ARA is provided by diet, directly from animal products and indirectly from the conversion of linoleic acid found in the vegetal oils. Linoleic acid and ARA amounts increased in the last 40 years period in the western diets. Therefore the influence of dietary ARA on the occurrence of AD is an important issue for the prevention of the disease. Unfortunately, only two studies were performed on transgenic AD murine model to measure the impact of dietary ARA on the pathological process and found opposite results on Aβ production and deposition 62, 63 . Therefore, additional studies are necessary to clarify the dietary ARA impact in AD and to identify the underlying mechanisms, keeping in mind the perspective of nutritionbased preventive strategies of AD.
